| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | 0.063 | 0.05 |
| mRNA | Compound 23 citrate | CTRPv2 | pan-cancer | AAC | 0.064 | 0.05 |
| mRNA | masitinib | CTRPv2 | pan-cancer | AAC | 0.069 | 0.05 |
| mRNA | parbendazole | CTRPv2 | pan-cancer | AAC | 0.058 | 0.05 |
| mRNA | tanespimycin:gemcitabine (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.061 | 0.06 |
| mRNA | piperlongumine | CTRPv2 | pan-cancer | AAC | 0.06 | 0.06 |
| mRNA | CIL41 | CTRPv2 | pan-cancer | AAC | 0.096 | 0.06 |
| mRNA | SB-225002 | CTRPv2 | pan-cancer | AAC | 0.057 | 0.06 |
| mRNA | TPCA-1 | CTRPv2 | pan-cancer | AAC | 0.06 | 0.06 |
| mRNA | necrosulfonamide | CTRPv2 | pan-cancer | AAC | 0.071 | 0.06 |